Pharos IBio Co Ltd

388870

Company Profile

  • Business description

    Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

  • Contact

    427beon-gil, Dongan-gu
    1407 and 1408, 38, Heungan-daero, Seongji Star With
    Gyeonggi-do, Gwanyang-dong
    Anyang-si
    KOR

    T: +82 313456170

    https://www.pharosibio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    33

Stocks News & Analysis

stocks

Overvalued ASX share as market underestimates downside risks

Growth outlook solid, but upside more than priced in.
stocks

New production imminent for undervalued ASX gas play

LNG project receives first commissioning gas.
stocks

Going into earnings, is Tesla stock a buy, a sell, or fairly valued?

Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,322.3038.500.41%
CAC 408,174.2014.39-0.18%
DAX 4023,830.99441.20-1.82%
Dow JONES (US)46,190.61238.370.52%
FTSE 1009,354.5781.52-0.86%
HKSE25,854.98607.882.41%
NASDAQ22,679.97117.440.52%
Nikkei 22548,899.561,317.412.77%
NZX 50 Index13,344.9655.750.42%
S&P 5006,664.0134.940.53%
S&P/ASX 2009,030.1041.900.47%
SSE Composite Index3,866.0926.340.69%

Market Movers